TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03524209

Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous instrumentation of the thoracolumbar spine
Description: The spine is stabilized cranially and caudally of the level of spondylodiscitis. The percutaneous instrumentation consists of a rod and pedicle screw construct. The vertebrae are instrumented through minimal skin incisions using a fluoroscopic guidance or a spinal navigation system based on 3D imaging.

Intervention type: OTHER
Group type: OTHER
Intervention: Brace
Description: Brace treatment is associated in patients presenting back pain and a risk for vertebral body collapse due to infection with subsequent kyphotic deformity of the thoracolumbar spine
Study: NCT03011021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Receive insulin following clinician's instruction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Receive insulin following clinician's instruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Receive insulin following clinician's instruction.
Study: NCT03491592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Physical Activity Intervention
Description: Participants in the Enhanced Intervention arm will receive all the intervention components of the Original Intervention described above plus: 1) text messages and adaptive goal-setting to drive participants back to the website and keep them there longer, and 2) data-driven, technology supported enhanced intervention content targeting theoretical constructs that influenced PA behavior in Latinas from the parent study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Original Physical Activity Intervention
Description: Participants in the Original Physical Activity intervention arm of the study will receive the original Spanish language, motivationally-tailored, Internet-based physical activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
Study: NCT03989505

Intervention type: DIAGNOSTIC_TEST
Intervention: blood-draw for biomarker analyses
Description: Blood will be drawn at three time-points: immediately before catherization, 12-24 hours after catheterization and 4-8 weeks after discharge. Creatinine will be measured for endpoint definition, while the markers urea, CRP (C-reactive protein), NGAL (neutrophil gelatinase-associated lipocalin), KIM-1 (kidney injury marker-1), cystatin C, suPAR (soluble urokinase-type plasminogen activator receptor), and penKid will be measured as biomarkers of interest.
Study: NCT01256632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: All study eyes will receive 0.5mg, of intravitreous monthly injections of ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: All study eyes will receive 0.5mg, of intravitreous monthly injections of ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
Study: NCT00499616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT03416777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pesco-vegetarian diet
Description: Diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish (1 serving = 150 g), for a total amount of 450 g per week. Diet will contain other sources of proteins (e.g. eggs, dairy, legumes/beans). There is suggestive evidence that fish and vegetable consumption has protective effects against CRC (Vieira et al., 2017).
Study: NCT02123979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupro® transdermal patch/placebo
Description: 8mg transdermal patch Neupro® transdermal patch/placebo
Study: NCT00499616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study: NCT02123979

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neupro® transdermal patch/placebo
Description: 8mg transdermal patch Neupro® transdermal patch/placebo
Study: NCT03929393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Movement
Description: The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social suppo
Study: NCT00499616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given orally
Study: NCT03587597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket shield technique
Description: socket shield technique with immediate temporization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional immediate implant placement with immediate temporization
Description: conventional immediate implant placement with immediate temporization
Study: NCT00591799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Jarvik 2000 Ventricular Assist System
Description: Jarvik 2000 Heart implantation is intended for patient's with end-stage heart failure who are approved heart transplant candidates - who meet all of the study's inclusion criteria and none of its exclusion criteria.
Study: NCT02254824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xuezhikang
Description: Xuezhikang

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: Lifestyle modification

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: Lifestyle modification
Study: NCT00499616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.
Study: NCT03929393

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Keys to Health & Wellbeing
Description: This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
Study: NCT00499616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Administered subcutaneously or by IV beginning 24-48 hrs after the last dose of chemotherapy \& continuing daily until the ANC is greater than or equal to 1500 following the myelosuppressive nadir . Supportive care given to stimulate neutrophil recovery following chemotherapy and to shorten the duration of chemotherapy-induced neutropenia. On ANBL0531 the use of filgrastim was required for patients less than 60 days of age and was optional for other patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Administered subcutaneously or by IV beginning 24-48 hrs after the last dose of chemotherapy \& continuing daily until the ANC is greater than or equal to 1500 following the myelosuppressive nadir . Supportive care given to stimulate neutrophil recovery following chemotherapy and to shorten the duration of chemotherapy-induced neutropenia. On ANBL0531 the use of filgrastim was required for patients less than 60 days of age and was optional for other patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Administered subcutaneously or by IV beginning 24-48 hrs after the last dose of chemotherapy \& continuing daily until the ANC is greater than or equal to 1500 following the myelosuppressive nadir . Supportive care given to stimulate neutrophil recovery following chemotherapy and to shorten the duration of chemotherapy-induced neutropenia. On ANBL0531 the use of filgrastim was required for patients less than 60 days of age and was optional for other patients.
Study: NCT02254824

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: Lifestyle modification
Study: NCT01722799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug elluting Balloon (DEB)
Description: Percutaneous transluminal coronary angioplasty with drug elluting ballon and Bare metal stent for rescue.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug elluting coronary stent (DES)
Description: Percutaneous transluminal coronary angioplasty (PTCA) with stent
Study: NCT01930578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with 0.9% normal saline
Description: An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design.
Study: NCT04690426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRV-101
Description: Coxsackie Virus B vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRV-101
Description: Coxsackie Virus B vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03272152

Intervention type: GENETIC
Intervention: Genome-wide DNA methylation
Description: Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.

Intervention type: GENETIC
Intervention: Genome-wide DNA methylation
Description: Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.

Intervention type: GENETIC
Intervention: Genome-wide DNA methylation
Description: Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.
Study: NCT01930578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with 0.9% normal saline
Description: An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with 0.9% normal saline
Description: An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design.
Study: NCT05945407

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Indication-extended Fertility-sparing Therapy
Description: Patients will receive medroxyprogesterone acetate (FARLUTAL) 250-500mg/d or megestrol acetate (YiLiZhi) 160-320mg/d orally. If there is no response after 6 months of treatment, change the regimen to levonorgestrel intrauterine system (Mirena) and gonadotropin-releasing hormone agonist (Leuprorelin, Goserelin or Triptorelin) 3.75mg/28d injection subcutaneously. After complete remission, the same regimen will be used for consolidation treatment for another 1-3 months. Subsequently, if the patient has no intention of pregnancy, render maintenance treatment (Mirena, Progesterone, Dydrogesterone, or combined oral contraceptive). Otherwise, the patient will be encouraged to conceive either by an expectation for 3-6 months, or by assisted reproductive technology. Indications for stopping fertility-sparing therapy: 1) disease progression; 2) no response after 9 months of treatment; 3) repeated recurrence; 4) no longer require sparing fertility; 5) serious adverse reactions.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Indication-extended Fertility-sparing Therapy
Description: Patients will receive medroxyprogesterone acetate (FARLUTAL) 250-500mg/d or megestrol acetate (YiLiZhi) 160-320mg/d orally. If there is no response after 6 months of treatment, change the regimen to levonorgestrel intrauterine system (Mirena) and gonadotropin-releasing hormone agonist (Leuprorelin, Goserelin or Triptorelin) 3.75mg/28d injection subcutaneously. After complete remission, the same regimen will be used for consolidation treatment for another 1-3 months. Subsequently, if the patient has no intention of pregnancy, render maintenance treatment (Mirena, Progesterone, Dydrogesterone, or combined oral contraceptive). Otherwise, the patient will be encouraged to conceive either by an expectation for 3-6 months, or by assisted reproductive technology. Indications for stopping fertility-sparing therapy: 1) disease progression; 2) no response after 9 months of treatment; 3) repeated recurrence; 4) no longer require sparing fertility; 5) serious adverse reactions.
Study: NCT01604772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02052635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Single loading dose of 180mg of ticagrelor at time of bivalirudin administration. Beginning 12 hrs following study drug administration, all pts in the ticagrelor arm will receive ticagrelor 90 mg (maintenance dose) approximately every 12 hrs until Follow-up telephone contact.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Single loading oral dose of 600 mg of clopidogrel will be given at time of bivalirudin administration. Beginning 4 hrs following study drug administration, all pts in the clopidorgrel arm will receive ticagrelor 180 mg for the loading dose, followed by 90 mg maintenance dose approximately every 12 hours until the Follow-up telephone contact.
Study: NCT01571791

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: to receive saline infusion and intravenous fentanyl boluses, at 30 min before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac-Lidocaine
Description: receive ketorolac-lidocaine infusion and intravenous saline boluses , at 30 min before induction of anesthesia
Study: NCT00817063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alitretinoin
Description: Patients receive alitretinoin 30mg one capsule daily for up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients receive matching placebo for up to 24 weeks
Study: NCT00651846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yasmin (DRSP 3mg/EE 0.03 mg)
Description: The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (3mg DRSP/0.03 mgEE). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microgynon (LNG 0.15 mg/EE 0.03 mg)
Description: The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (LNG 0.15 mg/EE 0.03 mg). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
Study: NCT00025337

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT01930578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with D5+ 0.45 saline
Description: An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design.
Study: NCT03492177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selexipag (Uptravi)
Description: Film-coated tablets for oral administration
Study: NCT04451772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Capsule; Oral
Study: NCT00025337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study: NCT04451772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Capsule; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Capsule; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Capsule; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Capsule; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Elsubrutinib
Description: Capsule; Oral
Study: NCT00025337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT00671749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adapalene gel, 0.3%
Description: Applied once daily at bedtime
Study: NCT00671749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clindamycin/benzoyl peroxide gel
Description: Applied once daily in the morning
Study: NCT00529035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Dose will vary depending upon when participant enters the trial: Given as a daily injection under the skin for 8 weeks.
Study: NCT02515227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized monoclonal antibody (mAb) specific for PD-1.
Study: NCT02463383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Tab 400 MG
Description: 400mg ibuprofen is provided and an alcohol challenge (0.4g/kg bw) is given 30min later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Tab 400 MG
Description: 400mg ibuprofen is provided and an alcohol challenge (0.4g/kg bw) is given 30min later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tab
Description: A placebo tablet is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
Study: NCT01930578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with D5+ 0.45 saline
Description: An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with D5
Description: An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design.
Study: NCT02463383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tab
Description: A placebo tablet is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
Study: NCT01930578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with D5
Description: An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design.